Skip to main content

Editorial reviews. Affiliate fees from some providers don't affect rankings. Disclosure

No advertiser influenceAffiliate fees disclosedReviewed by board-certified clinicians

Home · Coverage

Does Aetna cover Zepbound в 2026?

Depends on your specific plan

Zepbound (generic: tirzepatide) is FDA-approved для chronic weight management. Coverage hinges on whether your employer plan includes an obesity-treatment benefit — many commercial plans exclude it.

Last verified 2026-06-01. Coverage changes — always confirm with your plan administrator.

1. Aetna coverage status for Zepbound

Depends on your specific plan. Coverage swings widely between employer plans. PPO + HMO tiers, group vs individual, и state regulation all factor.

2. Prior-authorization criteria

Aetna typically requires the prescriber к document:

  • BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, sleep apnea)
  • Documented weight-management attempts (diet + exercise) over 6+ months
  • Plan benefit must include obesity-treatment coverage (most commercial plans exclude this benefit)
  • Provider attestation + supervised treatment plan

3. Step-therapy requirements

Before approving Zepbound, Aetna typically requires trial + documented failure of:

  • Lifestyle program documentation
  • Older anti-obesity meds (phentermine, Saxenda) — varies by plan

4. Common reasons for denial

  • Plan benefit excludes obesity treatment
  • BMI below threshold
  • Insufficient documented lifestyle attempts
  • Comorbidity not adequately documented

5. If denied — how к appeal

If denied, request the written denial letter (legally required), then file а written appeal within the timeline stated. Include: physician letter of medical necessity, lab values, treatment history, and any peer-reviewed clinical evidence. If first appeal fails, escalate к external review through your state insurance commissioner.

Tip: request your physician's office submit а formal "letter of medical necessity" — these significantly improve appeal outcomes.

6. If uncovered — affordable alternatives

If Aetna denies coverage и appeal fails, cash-pay options exist:

  • Manufacturer savings programs — Lilly LillyDirect direct-to-consumer pricing (verify eligibility on the manufacturer site)
  • Compounded tirzepatide via licensed compounding pharmacies — typically $200-400/mo cash-pay
  • See our Zepbound provider list для current pricing across telehealth programs

Sources

Related coverage guides

Aetna + MounjaroAetna + OzempicAetna + WegovyAnthem + ZepboundBlue Cross Blue Shield + ZepboundCigna + ZepboundHumana + ZepboundUnitedHealthcare + Zepbound